What’s New in Rezum: a Transurethral Water Vapour Therapy for BPH
- 17 Downloads
Purpose of Review
Rezum is a new minimally invasive treatment for benign prostate enlargement using thermal transurethral water vapour therapy. We review the evidence with advantages and disadvantages of this technique.
There are five studies reported including a randomised control trial looking at the outcomes of Rezum. The outcomes show an IPSS reduction by 45–60%, QoL improvement with a score reduction of 37–59%, the Qmax improvement by 44–72% and the PVR reduction by 20–38%.
Convective water vapour therapy using the Rezum system has been shown to have successful outcomes in the treatment of LUTS resulting from BPH. The reported complications are infrequent and often minor, and it seems to be relatively cost-effective.
KeywordsRezum Water vapour therapy BPH LUTS Minimally invasive therapy TURP
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Compliance with Ethical Standards
Conflict of Interest
Zachary Green and Jennifer Westwood each declare no potential conflicts of interest.
Bhaskar K. Somani is a section editor for Current Urology Reports.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.EAU Guidelines. Edn. Presented at the EAU Annual Congress Copenhagen. Arnhem: EAU Guidelines Office; 2018. https://uroweb.org/guidelines/compilations-of-all-guidelines. Accessed 3 March 2019.
- 6.Van AB, Barkin J, Elterman DS, Czerniak B, Dinney C, McConkey D, et al. Hyperplasia : a review. Curr Opin Oncol. 2014;23:863–910.Google Scholar
- 7.Foster HE, Barry MJ, Dahm P, Gandhi MC, Kaplan SA, Kohler TS, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. J Urol. 2018;Google Scholar
- 10.•• McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology [internet]. Elsevier Inc.; 2019;126:171–179. This paper outlines data collected in the only double blinded randomised control trial using Rezum. As of 2019 data are avialble for four years post implementation of the therapy. The study also features the largest number of participants. CrossRefGoogle Scholar
- 11.National Institute for Health and Care Excellence (NICE). Medtech innovation briefing (MIB158). Rezum for treating benign prostatic hyperplasia. London: NICE; 2018.Google Scholar
- 12.• Mynderse LA, Hanson D, Robb RA, Pacik D, Vit V, Varga G et al. Rezu¯m system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology. Elsevier Inc.; 2015;86(1):122–7. This paper provided objective data on the efficacy of Rezum and its viability for bringing about reduction in prostatic volume. CrossRefGoogle Scholar
- 14.Gittelman MC, Gange SN, Patel K, Roehrborn CG, Beahrs JR, Levin RM, et al. Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol Elsevier Ltd. 2016;197(6):1507–16.PubMedGoogle Scholar
- 17.Shore ND, McVary KT, Roehrborn CG, Kaminetsky J, Dixon CM, Cantrill CH, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol Elsevier Ltd. 2015;195(5):1529–38.PubMedGoogle Scholar
- 18.Roehrborn CG, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol. 2017;197:1507–16.CrossRefGoogle Scholar
- 19.Darson MF, Alexander EE, Schiffman ZJ, Lewitton M, Light RA, Sutton MA, et al. Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezūm system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Res Rep Urol. 2017;9:159–68.PubMedPubMedCentralGoogle Scholar
- 21.Gupta N, Rogers T, Holland B, Helo S, Dynda D, McVary KT. Three-year treatment outcomes of water vapor thermal therapy compared to doxazosin, finasteride and combination drug therapy in men with benign prostatic hyperplasia: cohort data from the MTOPS trial. J Urol [Internet] Elsevier Ltd. 2018;200(2):405–13.CrossRefGoogle Scholar
- 22.McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: randomized controlled study. J Sex Med [Internet] Elsevier. 2016;13(6):924–33.CrossRefGoogle Scholar
- 24.• Ulchaker J, Martinson M. Analyzing the Cost-Effectiveness of Six Therapies for Treating Lower Urinary Tract Symptoms Due To Benign Prostatic Hyperplasia. J Urol. 2018;199:29–43 In-depth analysis of the costs associated with new minimally invasive prosate therapies. Highlights potential for implementation within various health services.CrossRefGoogle Scholar